The Antiangiogenic Effects of Tamoxifen might be Attributed to Receptor Binding Capacity of its Solvent Dimethylsulfoxide in Breast Cancer: A Molecular Docking Study

Creative Commons License

Koçak O., Taskin N. D., ŞİMŞEK E.

JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL, vol.30, no.2, 2019 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 30 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.9734/jpri/2019/v30i230265
  • Journal Name: JOURNAL OF PHARMACEUTICAL RESEARCH INTERNATIONAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Keywords: Tamoxifen, DMSO, IFN gamma, TNF alpha, molecular docking, angiogenesis, breast cancer, EBENUS-BOISSIERI BARBEY, CRYSTAL-STRUCTURE, CYTOTOXICITY
  • Akdeniz University Affiliated: Yes

Abstract

Aim: Tamoxifen, a Dimethyl sulfoxide (DMSO)-soluble chemotherapeutic, is widely used in the treatment of breast cancer. Tamoxifen has an anti-angiogenic effect especially on breast tumor cells by blocking VEGF(Vascular Endothelial Growth Factor) production. On the other hand, according to our previously studies, we demonstrated that DMSO could mimics the cytotoxic effects of Thalidomide in 4T1 mouse breast cancer cells and is related with the anti-angiogenic response of HeLa cells. At this point of view, the aim of this study was to determine the possible binding effects of DMSO on certain cell surface receptors.